Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections.

Abstract

We review the changes in incidences of HIV-related opportunistic infections and the safety of discontinuation of primary and secondary prophylaxis for HIV-related opportunistic infections in patients achieving immune restoration after the introduction of highly active antiretroviral therapy (HAART). HIV-related opportunistic infections continue to occur in patients who are newly diagnosed with HIV infection, those in the early course of HAART or non-adherent to HIV care and HAART, and those in whom non-HIV-related infections have emerged as a significant cause of morbidity and mortality in the post-HAART era. Clinical studies of patients with tuberculosis and HIV co-infection are reviewed to provide appropriate regimen combinations of rifamycins and antiretrovirals, which have varying degrees of drug-drug interactions that have posed challenges in the management of tuberculosis as well as HIV infection.

• Authors: Chien-Ching Hung, Shan-Chwen Chang
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 54 Issue 5 Pg. 849-53 (Nov 2004) ISSN: 0305-7453 [Print] England
• PMID: 15456733 (Publication Type: Journal Article, Review)

Chemical References

• Rifamycins

Topics

• AIDS-Related Opportunistic Infections (epidemiology, prevention & control)
• Antiretroviral Therapy, Highly Active
• Bacterial Infections (epidemiology, prevention & control)
• Humans
• Incidence
• Mycoses (epidemiology, prevention & control)
• Parasitic Diseases (epidemiology, prevention & control)
• Rifamycins (therapeutic use)
• Tuberculosis (epidemiology, prevention & control)
• Virus Diseases (epidemiology, prevention & control)